The company achieved self-affirmed GRAS (Generally recognized as safe) status for Solein in the US in September 2024. Since then, Solar Foods has registered its Factory 01 production facility in Vantaa, Finland, with the US Food and Drug Administration (FDA) and completed other requirements to commercialize Solein in the United States. 

Solar foods announced on Wednesday that a total of 51,942 new shares have been subscribed for under the 1/2023 and 1/2024 stock option plans.

The H1 figures for Solar Foods were already largely known, but an insignificant change in the timing of earnings resulted in a clear difference compared to the company's previously communicated earnings estimate. The most important news was the Capital Markets Day on December 10, where we will seek visibility on major strategic directions.

Despite its early stage of development, the company is a leading global player in a rapidly growing and evolving industry. The key risk to the stock is the capital required to scale up production, which we believe will be the dividing line between successful cellular agriculture companies and others. If cellular agriculture delivers, we expect the winners of the industry to be rewarded with significant first-mover advantages and an attractive long-term investment horizon.

The Finnish protein production revolutioniser Solar Foods Oyj (hereinafter “Solar Foods” or “the Company”) is planning a listing and application for admission of shares to trading on the Nasdaq First North Growth Market Finland marketplace maintained by Nasdaq Helsinki Ltd. The planned listing would be carried out in September as a technical listing, i.e. no share issue or sale will be arranged in connection with it.